CARDIAC TROPONIN-T AND CREATINE-KINASE MB MASS CONCENTRATIONS IN CHILDREN RECEIVING ANTHRACYCLINE CHEMOTHERAPY

Citation
Fm. Fink et al., CARDIAC TROPONIN-T AND CREATINE-KINASE MB MASS CONCENTRATIONS IN CHILDREN RECEIVING ANTHRACYCLINE CHEMOTHERAPY, Medical and pediatric oncology, 25(3), 1995, pp. 185-189
Citations number
35
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology,Pediatrics
ISSN journal
0098-1532
Volume
25
Issue
3
Year of publication
1995
Pages
185 - 189
Database
ISI
SICI code
0098-1532(1995)25:3<185:CTACMM>2.0.ZU;2-H
Abstract
Anthracyclines (doxorubicin, daunorubicin, and derivatives) are among the most effective antineoplastic drugs for pediatric cancer with dose -limiting acute and longterm cardiotoxicity. The exact mechanism of th e development of cardiomyopathy is still not clear. Anthracyclines may induce subclinical acute myocardial injury leading to lysis of a limi ted number of myocytes. Alternatively, myocytes may experience a trans ient loss of cytoplasmic membrane integrity. Both conditions may lead to a transient efflux of small amounts of cytoplasmic enzymes and othe r proteins specific to the heart muscle fibers. To test these hypothes es we assayed plasma creatine kinase (CK) MB mass and cardiac specific troponin T (TnT). CKMB may be released even in case of reversible cel l membrane injury, while prolonged elevation of TnT is the most sensit ive and specific marker of limited myocardial necrosis. Thirty-five an thracycline-containing chemotherapy courses in 22 children with cancer were analyzed. CKMB mass and TnT concentrations were within the norma l range in all children before anthracycline therapy. Within 72 hours from anthracycline therapy no increment of one of these two marker pro teins was detected (ANOVA for repeated measures, P = 0.94 [TnT] and 0. 25 [CKMB]). We conclude that only minimal if any acute necroses of car diac myocytes occur after anthracycline therapy. Even membrane integri ty appears to be maintained within the first 3 days after anthracyclin e therapy, in the absence of electrocardiographic or echocardiographic signs of acute cardiotoxicity. (C) 1995 Wiley-Liss, Inc.